Papilocare® Gel, a Spanish-developed treatment, shows promise in aiding HPV recovery, backed by robust clinical evidence and international recognition.
For years, women dealing with persistent Human Papillomavirus (HPV) infections had little recourse beyond observation and monitoring. While periodic check-ups were essential, options to actively address the condition remained minimal. Enter Papilocare® Gel Vaginal, a Spanish innovation that’s changing the narrative for HPV management through extensive clinical research and experience in real-world applications.
HPV remains one of the most common sexually transmitted infections, often clearing naturally due to the body’s immune response, particularly in younger women. However, as age increases, the body’s ability to combat the virus diminishes, posing risks such as cervical lesions and subsequent complications. Historically, the clinical approach to HPV focused largely on watchful waiting.
A Complementary Option in Scarce Territory
Developed by Procare Health, Papilocare® Gel Vaginal was designed to serve as an adjunct treatment for lesions linked to HPV. Its uniqueness lies not just in the formulation but in the delivery technology; the ingredients are packaged in small capsules that penetrate deeper into tissues, releasing their active components at the site of infection initiation.
Since its launch in 2016, the company has strived to blend innovation with clinical research, collaborating with gynecology, colposcopy, and gynecological oncology specialists. This effort has aimed to assess Papilocare®’s effectiveness in real-world clinical settings and generate data to support its role as an enhancement to usual patient monitoring.
Over a decade of research and numerous independent studies across various countries corroborate the same findings, establishing Papilocare® as a reliable option for women living with HPV.
Evidence Built Test by Test
Scientific interest is driven by a compendium of studies yielding consistent outcomes, rather than isolated results. The PALOMA 1 trial indicates that 81.8% of women using Papilocare® eradicated the virus within six months, compared to just 40% in those undergoing routine observation alone. In the follow-up PALOMA 2 study, similar results emerged, with 88.5% elimination versus 53.6% control. One year later, the effect persisted for 77.3% of participants. The PAPILOCAN study further reinforces these findings, revealing an 80% success rate among those using Papilocare® against 45% in a control group. Three randomized controlled trials conducted with diverse methodologies draw parallel conclusions — the use of Papilocare® significantly enhances the likelihood of viral clearance compared to mere observation.
“Our goal has always been to back each step with scientific evidence,” remarks Gina Vich, Medical Advisor at Procare Health. “We’re not just referencing a solitary study, but assembling a robust body of consistent results and real-world clinical experience. This synergy drives our growing international recognition.”
Visibility in Prominent Scientific Forums
The rising interest in this area of research is highlighted by presentations at specialized congresses. During the World Congress of the International Federation of Cervical Pathology and Colposcopy (IFCPC) in Versailles, Papilocare® was a significant point of discussion, featured four times in the official scientific program.
This event underscored vaccination as the primary preventative measure against HPV, notably when administered prior to first exposure in youth. Concurrently, expert sessions recognized an ongoing need for complementary options for women with existing persistent infections. Here, Papilocare®’s outcomes became pivotal in various presentations and discussions about HPV management and associated cervical lesions.
Independent Research Broadens the Evidence Base
One hallmark of the product’s scientific journey is the emergence of studies led by independent international teams. Recently, a group spearheaded by Professor Murat Gültekin from Hacettepe University, who also heads the prevention sector of the European Society of Gynaecological Oncology (ESGO), published a study in the journal Diseases that analyzed data from 600 patients.
The findings were compelling: 89.3% of women using Papilocare® cleared the virus, in contrast to 44.7% among non-users, nearly doubling the efficacy. Furthermore, 88.4% of lesions regressed in the treatment group compared to 60.4% without treatment. This pattern persisted even after considering external factors, reinforcing the outcomes' reliability.
In parallel, various European research teams, including Danish specialists, are launching new studies. This indicates that Papilocare® has moved beyond initial interest and is being rigorously explored by external researchers.
A Spanish Innovation with Global Ambitions
This initiative finds relevance as the medical research community recognizes a historical underinvestment in addressing diseases and healthcare needs specific to women. Since its inception, Procare Health has prioritized female health, aiming to build its own scientific base in an area often overlooked.
“Fostering innovation in women’s health requires patience, thoroughness, and partnerships with healthcare professionals,” states Olalla Calvo, Medical Advisor at Procare Health. “We’re committed to contributing further through new studies and providing tools to enhance patient quality of life.”
Over a decade of research and mounting evidence from various clinical trials cement Papilocare®’s position as a noteworthy Spanish advancement steadily gaining traction. While vaccination and early diagnosis remain critical to HPV prevention, the research now aims to expand available options and understand how adjunct tools can effectively complement standard clinical follow-up. In this context, Papilocare® is establishing itself firmly in international scientific dialogues.
Discussion
Sign in to join the discussion.